Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 7/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.53 |
| ▸ | HTT | P42858 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.53 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1036983 | 0.81 | MEN1 (0.69) | KDM4EPOLBMEN1KMT2AHTT | |
| SCHEMBL1040215 | 0.79 | ALDH1A1 (0.59) | KDM4EPOLBMEN1KMT2AHTT | |
| SCHEMBL1040743 | 0.76 | ALDH1A1 (0.60) | POLBMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL6183591 | 0.74 | KMT2A (0.39) | KDM4EPOLBMEN1KMT2AHTT | |
| SCHEMBL16492687 | 0.74 | KDM4E (0.58) | KDM4EPOLBMEN1KMT2AHTT | |
| SCHEMBL6087090 | 0.72 | MEN1 (0.60) | KDM4EPOLBMEN1KMT2AHTT | |
| SCHEMBL1038559 | 0.72 | LMNA (0.51) | MEN1KMT2AHTTALDH1A1LMNA | |
| SCHEMBL7258442 | 0.72 | KDM4E (0.57) | KDM4EPOLBMEN1KMT2AHTT | |
| SCHEMBL19259536 | 0.72 | KDM4E (0.57) | KDM4EPOLBMEN1KMT2AHTT | |
| SCHEMBL15556986 | 0.72 | MEN1 (0.67) | KDM4EPOLBMEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114149364-A | Preparation method of N- (6-methoxypyridine-3-yl) -3-methylpyridine-2-sulfonamide | 无锡捷化医药科技有限公司 | 2022-03-08 | — | — | CN | claimed |
| CN-114149364-A | Preparation method of N- (6-methoxypyridine-3-yl) -3-methylpyridine-2-sulfonamide | 无锡捷化医药科技有限公司 | 2022-03-08 | — | — | CN | disclosed |
| CN-114149364-A | Preparation method of N- (6-methoxypyridine-3-yl) -3-methylpyridine-2-sulfonamide | 无锡捷化医药科技有限公司 | 2022-03-08 | — | — | CN | disclosed |
| CN-114149364-A | Preparation method of N- (6-methoxypyridine-3-yl) -3-methylpyridine-2-sulfonamide | 无锡捷化医药科技有限公司 | 2022-03-08 | — | — | CN | disclosed |
| EP-1554239-B1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-01-26 | — | — | EP | disclosed |
| US-7435815-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-10-14 | — | — | US | disclosed |
| US-7435815-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-10-14 | — | — | US | disclosed |
| US-20070244156-A1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-18 | — | — | US | disclosed |
| US-20070244156-A1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-18 | — | — | US | disclosed |
| US-7279578-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-09 | — | — | US | disclosed |
| US-7279578-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244156-A1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES | HCRTR2, HCRTR1, GIPR | KDM4E 1700/4885POLB 4868/4885MEN1 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.